Contact Us | Log In
Search
Sensex: 33342.8 +236.00 Gold: Rs.29653.00
Nifty: 10283.6 +68.80 Silver: Rs.39847.00
Aurobindo Pharma Q2FY18: Injectable Portfolio, New Launches to Drive US Biz; Maintain BUY - IndiaNotes.com
Aurobindo Pharma Q2FY18: Injectable Portfolio, New Launches to Drive US Biz; Maintain BUY
Reliance Securities | Published: 14 Nov, 2017  | Source : IndiaNotes.com

Looking ahead, we expect strong ramp-up in Europe business’ operating performance as well as healthy sales growth in the US (new launches, ramp-up in injectable biz, strong pipeline and diversified product-mix). We expect ARBP’s sales and PAT to witness 10.4% & 15.1% CAGR through FY17-19E, respectively with healthy return ratios (RoE/RoCE at 20.1%/21.5%). We reiterate our BUY recommendation on the stock with a revised Target Price of Rs810 (from Rs 800 earlier).


Link to the PDF



About Reliance Securities

Reliance Securities, the broking arm of Reliance Capital, is one of the India’s leading retail broking houses, providing customers with access to equities, derivatives, currency, IPOs, mutual funds, bonds, and corporate FDs amongst others. The large array of financial offerings helps customers fulfilling their investment objectives on one platform. Focus on timely & error-free execution represents its core strength. Their best in class research offerings, high degree of compliance with stock exchange regulations, ethical business standards, & strong risk management capabilities; Reliance Securities positions itself amongst strong & innovative brands in the financial services space.


For more information please write in to editor@indianotes.com


Disclaimer: The author has taken due care and caution to compile and analyse the data. The opinions expressed above are only the views of the author, and not a recommendation to buy or sell. Neither the author nor IndiaNotes.com accept any liability whatsoever arising from the use of any of the above contents.

 

logo
BSE : 707.70 -5.40
(-0.76%)
NSE : 708.80 -4.40
(-0.62%)
Read More